Core Viewpoint - Hainan Wenqin intends to reduce its stake in Bluefeng Biochemical by up to 11,267,818 shares, representing a maximum of 3% of the company's total share capital, due to funding needs [1] Group 1: Shareholding and Reduction Plan - Hainan Wenqin currently holds 23,793,411 shares in Bluefeng Biochemical, accounting for 6.3349% of the total share capital [1] - The reduction will occur within three months after the announcement, utilizing both centralized bidding and block trading methods [1] - The maximum shares to be reduced via centralized bidding will not exceed 1% of the total share capital, while block trading will not exceed 2% [1] Group 2: Impact on Company Structure - The reduction plan will not lead to a change in the control of the company, as Hainan Wenqin is not a controlling shareholder or actual controller [1] - There will be no impact on the company's governance structure, equity structure, or ongoing operations as a result of this reduction [1]

关于持股 5%以上股东减持股份预披露公告 证券代码：002513 证券简称：蓝丰生化 公告编号：2026-005 江苏蓝丰生物化工股份有限公司 持股 5%以上股东海南闻勤私募基金管理合伙企业（有限合伙）——闻勤顺 为 1 号私募证券投资基金保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 持有江苏蓝丰生物化工股份有限公司（以下简称"公司"或"本公司"）股 份 23,793,411 股，占本公司总股本比例 6.3349%的股东海南闻勤私募基金管理 合伙企业（有限合伙）——闻勤顺为 1 号私募证券投资基金（以下简称"海南闻 勤"）计划在本公告发布之日起 15 个交易日后的 3 个月内通过集中竞价交易和 大宗交易方式减持公司股份不超过 11,267,818 股，不超过公司总股本的 3%，其 中：以集中竞价交易方式减持的股份数量不超过公司总股本的 1%，以大宗交易 方式减持的股份数量不超过公司总股本的 2%。 公司于近日收到持股 5%以上股东海南闻勤发送的《关于江苏蓝丰生物化工 ...

Core Viewpoint - Hainan Wenqin Private Fund Management Partnership (Limited Partnership) plans to reduce its stake in Lanfeng Biochemical by up to 11.2678 million shares, representing 3% of the company's total share capital, within three months from the announcement date [1] Summary by Relevant Sections - **Shareholding Details** - The shareholder currently holds 23.7934 million shares, which accounts for 6.3349% of the total share capital of the company [1] - **Reduction Plan** - The reduction will occur through centralized bidding and block trading, with a maximum of 1% reduction through centralized bidding and 2% through block trading [1]

Group 1 - The core point of the article is that Lanfeng Biochemical announced the approval of a resolution regarding the change of the company's financial director during the 32nd meeting of its seventh board of directors [2]

蓝丰生化公告称，近日副总经理兼财务总监邢军因个人原因辞职，辞职后不在公司任职。其持有公司股 权激励限售股45万股，占总股本0.12%。2026年1月16日公司召开董事会，审议通过变更财务总监议 案，同意聘任彭志敏为副总经理兼财务总监，任期至第七届董事会任期届满。彭志敏曾任多家公司财务 相关职务，目前未持有公司股份，符合任职资格。 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2026-004 江苏蓝丰生物化工股份有限公司 关于变更财务总监的公告 彭志敏先生符合所任岗位的任职资格和要求，不存在《公司法》《公司章程》 及《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 中规定的不得担任公司高级管理人员的情形。 特此公告。 江苏蓝丰生物化工股份有限公司董事会 2026 年 1 月 16 日 1 附件：彭志敏先生简历 彭志敏先生，中国国籍，1970 年出生，无境外永久居留权，会计学专业， 本科学历，中级会计师。曾任中国电子科技集团公司第十一研究所会计主管、远 光软件股份有限公司多家子公司财务总监、世纪金源投资集团有限公司大健康板 块财务负责人、无锡兴华衡辉科技有限公司副总经理。 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 近日，江苏蓝丰生物化工股份有限公司（以下简称"公司"）董事会收到公 司副总经理兼财务总监邢军先生的辞职报告，其因个人原因不能履职，申请辞去 公司副总经理及财务总监职务，辞职后将不在公司担任任何职务。根据《中华人 民共和国公司法》（以下简称《公 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2026-003 江苏蓝丰生物化工股份有限公司 二、董事会会议审议情况 （一）审议通过《关于变更公司财务总监的议案》 近日，公司董事会收到公司副总经理兼财务总监邢军先生的辞职报告，其因 个人原因不能履职，申请辞去公司副总经理及财务总监职务，辞职后将不在公司 担任任何职务。为保证公司各项工作的顺利开展，公司拟聘任彭志敏先生为公司 副总经理兼财务总监，任期自第七届董事会第三十二次会议审议通过之日起计算， 至第七届董事会期满之日止。 本议案已经公司董事会提名委员会、审计委员会事前审议通过，并同意将本 议案提交董事会审议。 表决结果：8 票同意，0 票反对，0 票弃权。 具体详见 2026 年 1 月 17 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》《证券时报》《中国证券报》上的相 关公告。 第七届董事会第三十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第三十 ...

Market News - China will release December import and export data on January 14, with exports expected to grow by 3.0% year-on-year, down from 5.9% in November, while imports are anticipated to decline by 2.9% [3] - The trade balance for December 2025 will also be published on January 14, with total goods trade from January to November 2025 reaching 41.21 trillion yuan, a year-on-year increase of 3.6% [3] Commodity Futures - The Shanghai Futures Exchange will adjust the price limit for platinum and palladium futures contracts to 16% starting from January 13, 2026, with the trading margin standard set at 18% [4] Energy Outlook - The U.S. Energy Information Administration (EIA) will release its Short-Term Energy Outlook report on January 13, maintaining the WTI crude oil price forecast for 2025 at slightly below $69 per barrel [5] U.S. Economic Data - The U.S. will release December CPI data on January 13, with core CPI expected to rebound significantly, predicted at 0.36% by Morgan Stanley and 0.38% by Bloomberg, both higher than the average of 0.08% in October and November [6] - Key economic indicators including October and November PPI and November retail sales will also be released, with expectations of moderate PPI growth and a 0.7% rebound in retail sales for November [6] Federal Reserve - The Federal Reserve will publish its latest Beige Book on January 14, indicating that government shutdowns and AI applications have weakened the job market, while rising tariffs and healthcare costs have increased business expenses [7] Earnings Season - The earnings season for Q4 2025 will commence this week, with major banks including JPMorgan, Citigroup, and Goldman Sachs set to report [8] Sector Events - The second China eVTOL Innovation Development Conference is scheduled for January 15-16, 2026, in Shanghai, focusing on the new commercial era of eVTOL [10] - The fourth Data Center Liquid Cooling & AI Chip Thermal Management Supply Chain Conference will be held on January 14-15, 2026, in Shenzhen [10] - China's first comprehensive law in the nuclear energy sector, the Atomic Energy Law, will take effect on January 15, 2026 [11] Individual Company News - Hangyu Technology announced on January 11 that it has repurchased 752,800 shares, with plans to sell them within six months [13] - Huadong Medicine's subsidiary has developed a breakthrough treatment for severe hypertriglyceridemia, which has been included in the list of breakthrough therapies by the National Medical Products Administration [13] - Jingfeng Mingyuan plans to acquire 100% of Sichuan Yichong Technology Co., with a key review meeting scheduled for January 16, 2026 [13] - TSMC has commenced research on its next-generation 1.4nm process, with risk trial production expected to start in 2027 [13] Lock-up Expiration - From January 12 to January 16, 2026, 23 companies will have lock-up shares released, totaling 2.434 billion shares with a market value of approximately 48.56 billion yuan [16] - The highest market value of lock-up shares released on January 12 is from Tianxin Pharmaceutical at 7.84 billion yuan [17] New Stock Calendar - Two new stocks are set to be issued this week, with a total issuance of approximately 34 million shares and expected fundraising of 1.909 billion yuan [19] Market Outlook - The current market enthusiasm is driven by concentrated inflows from previously cautious funds, with expectations for continued momentum in thematic and small-cap stocks until after the Two Sessions [22] - Guojin Securities suggests that the spring market is likely to perform well, with a focus on AI investments and the recovery of domestic manufacturing [23] - Everbright Securities anticipates sustained market heat but warns of potential cooling as the Lunar New Year approaches, recommending attention to sectors like electronics and power equipment [24]

证券代码：002513 证券简称：蓝丰生化 公告编号：2026-002 江苏蓝丰生物化工股份有限公司 关于非公开发行股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、本次解除限售股份为江苏蓝丰生物化工股份有限公司（以下简称"公司"） 2015年度并购陕西方舟制药有限公司（以下简称"方舟制药"）非公开发行A股 股票，本次解除限售股份的数量为23,793,411股，占公司总股本的6.3349%； 二、本次申请解除限售股份股东相关承诺及履行情况 2、本次解除限售股份上市流通日为2026年1月12日。 一、公司非公开发行股份概况及股本变化情况 2015 年 11 月 20 日，中国证券监督管理委员会（以下简称"中国证监会"） 下发《关于核准江苏蓝丰生物化工股份有限公司向王宇等发行股份购买资产并募 集配套资金的批复》（证监许可[2015]2689 号），公司通过发行股份及支付现 金相结合的方式向陕西方舟制药有限公司（以下简称"方舟制药"）全体股东购 买其持有的方舟制药 100.00%股权。公司完成上述非公开发行股份购买资产并募 集配 ...

2015 年 11 月 20 日，中国证券监督管理委员会（以下简称"中国证监会"） 下发《关于核准江苏蓝丰生物化工股份有限公司向王宇等发行股份购买资产并募 集配套资金的批复》（证监许可[2015]2689 号），公司通过发行股份及支付现 金相结合的方式向陕西方舟制药有限公司（以下简称"方舟制药"）全体股东购 买其持有的方舟制药 100.00%股权。公司完成上述非公开发行股份购买资产并募 集配套资金相应股份登记手续，取得中国证券登记结算有限责任公司深圳分公司 出具的《股份登记申请受理确认书》。本次非公开发行新增股份的性质为有限售 条件流通股，上市日为 2016 年 2 月 26 日。本次非公开发行股份后，公司总股本 为 340,086,278 股。 该次非公开发行股份完成后至本公告披露日，公司总股本发生的变化如下： 1、2022 年 4 月 20 日，公司完成 2021 年限制性股票激励计划授予登记工作， 本次限制性股票授予登记人数 55 人，授予数量 3,385 万股，占公司总股本的 9.95%。本次限制性股票授予完成后，公司股份总数由 340,086,278 股增加至 373,936,278 股。具体内容详 ...